The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of SR-8541A in combination with botensilimab and balstilimab in subjects with refractory metastatic microsatellite stable colorectal cancer (MSS-CRC).
 
Alexis Weston
Employment - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
Patents, Royalties, Other Intellectual Property - Stingray Therapeutics
 
Monil Shah
Employment - Stingray Therapeutics
Leadership - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
Travel, Accommodations, Expenses - Stingray Therapeutics
 
Rend Williams
Employment - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
 
Trason Thode
Employment - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
Consulting or Advisory Role - Stingray Therapeutics
Patents, Royalties, Other Intellectual Property - Stingray Therapeutics
Travel, Accommodations, Expenses - Stingray Therapeutics
 
Linda McBride
Consulting or Advisory Role - Stingray Therapeutics
 
Srinivas Kasibhatla
Stock and Other Ownership Interests - Stingray Therapeutics
Consulting or Advisory Role - Stingray Therapeutics
Patents, Royalties, Other Intellectual Property - Stingray Therapeutics
Travel, Accommodations, Expenses - Stingray Therapeutics
 
Mohan Kaadige
Employment - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
Patents, Royalties, Other Intellectual Property - Stingray Therapeutics
Travel, Accommodations, Expenses - Stingray Therapeutics
 
Jonthan Northrup
Employment - Stingray Therapeutics
Leadership - Stingray Therapeutics
Stock and Other Ownership Interests - Stingray Therapeutics
Travel, Accommodations, Expenses - Stingray Therapeutics
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; Black Canyon Bio; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Agastiya Biotech; Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics; Incyte; Mirati Therapeutics; Novelty Nobility; Processa Pharmaceuticals, Inc; Rappta Therapeutics; Stemline Therapeutics
Research Funding - AADi; Adagene (Inst); Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Nimbus Therapeutics (Inst); Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof